Drug intelligence / Profile preview

A11

Development stage: Preclinical
Modality: Peptides

Overview

A11 is an ANXA1-derived peptide that is being investigated for its role in cancer immunotherapy. It functions by degrading Programmed cell death ligand 1 (PD-L1), a key immune checkpoint protein. By targeting PD-L1 degradation, A11 aims to inhibit tumor immune evasion, thereby offering a potential alternative strategy to current immune checkpoint inhibitors for treating multiple cancers.

Other names: ANXA1-derived peptide A11ANXA-1-derived peptide A11ANXA 1-derived peptide A11

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on A11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A11.

Explore the full profile